Mumbai, May 16 -- Revenue from operations increased 9.7% to Rs 1,915.80 crore in Q4 FY25.

The company reported pre-tax profit of Rs 206 crore in Q4 FY25 as against pre-tax loss of Rs 53.70 crore in Q4 FY24. EBITDA jumped 23% to Rs 357 crore during the quarter compared with Rs 289 crore in Q4 FY24. EBITDA margin expanded 210 bps to 18.4% in Q4 FY25 as against 16.3% in Q4 FY24.

In Q4 FY25, radiopharmaceuticals revenue grew by 15% YoY to Rs 296 crore, while revenue from radio pharmacy increased 7% YoY to Rs 600 crore in Q4 FY25. Revenue from Allergy Immunotherapy rose 2% YoY to Rs 192 crore and CDMO sterile injectables grew by 31% YoY to Rs 340 crore during the quarter .

Contract research, development and manufacturing organisation (CRDMO...